Invention:
This invention relates generally to neurodegenerative diseases and conditions, such as Alzheimer’s Disease, characterized with dysfunctional energetic function, unregulated microglia phagocytic activity and other related de-regulated biological functions. This invention further relates to methods and compositions for treating such neurodegenerative diseases and conditions with pharmaceutical compositions comprising one or more of agents capable of protecting neurons from cell death and unregulated microglia phagocytic activity.
Background:
Neurodegenerative diseases affect millions of people worldwide. Alzheimer’s Disease and Parkinson’s Disease are the most common neurodegenerative diseases. In the United States, as many as 6.2 million people may have Alzheimer’s disease, and nearly a million Americans are living with Parkinson’s Disease. The likelihood of developing a neurodegenerative disease rises dramatically with age. In the coming decades, more Americans may be affected by neurodegenerative diseases, especially as life expectancy increases.
Applications:
- Neurodegenerative disease, including but not limited to:
- Parkinson’s Disease
- Alzheimer’s Disease
- Migraines
- Epilepsy
Advantages:
- Diverse range of applications
- Can be used as treatment alone or as a supplement to existing therapeutics
